Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, announced the grant of 2,200 restricted stock units to a newly hired employee. This grant, approved by Atara's Board of Directors Compensation Committee, falls under the 2018 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4). The grant date is set for July 1, 2024, with the units vesting over four years. The first 25% will vest on the first quarterly vesting date following the first anniversary of the vesting commencement date. The remaining units will vest quarterly over the next three years, contingent on continuous employment with Atara. This disclosure complies with Nasdaq Listing Rule 5635(c)(4).
- None.
- None.
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240705905103/en/
Investor and Media Relations
Jason Awe, Ph.D.
Senior Director, Corporate Communications & Investor Relations
(805) 217-2287
jawe@atarabio.com
Source: Atara Biotherapeutics, Inc.
FAQ
What did Atara Biotherapeutics announce on July 1, 2024?
What is the vesting schedule for the restricted stock units granted by Atara Biotherapeutics?
How many restricted stock units did Atara Biotherapeutics grant to the new employee?
Under which rule did Atara Biotherapeutics report the recent stock grant?